Revive Therapeutics (RVVTF) Regulatory Update Archive.
April 12th, 2022 update. Discusses potentially halting the Study early due to positive efficacy based on other clinical outcomes evaluated such as the rate...
Deficiency of Glutathione as the Most Likely Cause of Serious Manifestations and Death in...
American Chemical Society
May 2020.
Higher rates of serious illness and death from coronavirus SARS-CoV-2 (COVID-19) infection among older people and those who have comorbidities...
Revive Therapeutics Announces Entry Into Phase III FDA Trial Using Glutathione Boosting Bucillamine.
Revive Therapeutics Announces U.S. FDA Recommendation to Proceed Directly Into A Phase 3 Confirmatory Clinical Trial
TORONTO, April 23, 2020 (GLOBE NEWSWIRE) --Revive Therapeutics Ltd.Ltd....
Latest article
GeoVax (GOVX) Surges 51% on Massive Volume Spike.
MonkeyPox and Gedeptin Related News Spark New Investor Interest.
MARKET BRIEF
On a quiet Thursday afternoon, the 30th, while we were nearing completion of an updated...
Paving Past Obstacles on the Path to US Biosecurity
GeoVax’s CEO calls on government support to bolster domestic biotechnology and keep pace with China.
National biosecurity has become a frequent topic of conversation in...
Dinner Presentation With BioStem Technologies, Inc. (BSEM) in Boca Raton, FL
LIVE QUOTE
LONGER TERM CHART
Contact Ray Oliver at Bear Creek Capital for details.
RECENT NEWS
PRESENTATION
https://youtu.be/Au-pIqDHyto?si=_JKFAhwT-vvLSFqe
WOUND CARE REPORT
Global Wound Care Market to Reach USD 30.48 Billion by...
